Top

Published in:

Open Access 01-12-2010 | Research article

Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways

Authors: Emanuele Marra, Paolo Uva, Valentina Viti, Valeria Simonelli, Eugenia Dogliotti, Emanuele De Rinaldis, Armin Lahm, Nicola La Monica, Alfredo Nicosia, Gennaro Ciliberto, Fabio Palombo

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI) anchored protein expressed not only in prostate but also in pancreas and bladder cancer as shown by immunohistochemistry and mRNA analysis. It has been targeted by monoclonal antibodies in preclinical animal models and more recently in a clinical trial in prostate cancer patients. The biological role played in tumor growth is presently unknown. In this report we have characterized the contribution of PSCA expression to tumor growth.

Methods

A bladder cell line was engineered to express a doxycycline (dox) regulated shRNA against PSCA. To shed light on the PSCA biological role in tumor growth, microarray analysis was carried out as a function of PSCA expression. Expression of gene set of interest was further analyzed by qPCR

Results

Down regulation of the PSCA expression was associated with reduced cell proliferation in vitro and in vivo. Mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shRNA against PSCA as revealed by GFP expression. Pathway analysis of deregulated genes suggests a statistical significant association between PSCA downregulation and activation of genes downstream of the IFNα/β receptor.

Conclusions

These experiments established for the first time a correlation between the level of PSCA expression and tumor growth and suggest a role of PSCA in counteracting the natural immune response.

Available only for authorised users

Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998, 95: 1735-1740. 10.1073/pnas.95.4.1735.CrossRefPubMedPubMedCentral

Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE: Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg. 2005, 29: 297-305. 10.1007/s00268-004-7843-0.CrossRefPubMed

Elsamman E, Fukumori T, Kasai T, Nakatsuji H, Nishitani MA, Toida K, Ali N, Kanayama HO: Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int. 2006, 97: 1202-1207. 10.1111/j.1464-410X.2006.06153.x.CrossRefPubMed

Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK: Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol. 2006, 13: 1645-1654. 10.1245/s10434-006-9029-5.CrossRefPubMed

Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE: Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007, 30: 396-405. 10.1097/CJI.0b013e318031b53b.CrossRefPubMed

Tanaka M, Komatsu N, Terakawa N, Yanagimoto Y, Oka M, Sasada T, Mine T, Gouhara S, Shichijo S, Okuda S, Itoh K: Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep. 2007, 18: 161-166.PubMed

Gu Z, Yamashiro J, Kono E, Reiter RE: Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005, 65: 9495-9500. 10.1158/0008-5472.CAN-05-2086.CrossRefPubMed

Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, et al: Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002, 62: 2546-2553.PubMed

Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 2001, 98: 2658-2663. 10.1073/pnas.051624698.CrossRefPubMedPubMedCentral

10.

Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Buchler MW, Reiter RE, Hines OJ: Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005, 31: 119-125. 10.1097/01.mpa.0000173459.81193.4d.CrossRefPubMed

11.

Gorter A, Meri S: Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999, 20: 576-582. 10.1016/S0167-5699(99)01537-6.CrossRefPubMed

12.

Jalkut MW, Reiter RE: Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol. 2002, 12: 401-406. 10.1097/00042307-200209000-00006.CrossRefPubMed

13.

Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, Dubey P: Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate. 2008, 68: 139-151. 10.1002/pros.20686.CrossRefPubMed

14.

Wiznerowicz M, Trono D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol. 2003, 77: 8957-8961. 10.1128/JVI.77.16.8957-8951.2003.CrossRefPubMedPubMedCentral

15.

Elia L, Mennuni C, Storto M, Podda S, Calvaruso F, Salucci V, Aurisicchio L, Scarito A, Ciliberto G, La Monica N, Palombo F: Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers. Eur J Immunol. 2006, 36: 1337-1349. 10.1002/eji.200535514.CrossRefPubMed

16.

D'Errico M, Rinaldis ED, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, Palli D, et al: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer. 2008, 45 (3): 461-9. 10.1016/j.ejca.2008.10.032.CrossRefPubMed

17.

Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31: e15-10.1093/nar/gng015.CrossRefPubMedPubMedCentral

18.

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000, 25: 25-29. 10.1038/75556.CrossRefPubMedPubMedCentral

19.

Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28: 27-30. 10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

20.

Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D, Bork P, Buillard V, Cerutti L, Copley R, et al: New developments in the InterPro database. Nucleic Acids Res. 2007, 35: D224-228. 10.1093/nar/gkl841.CrossRefPubMedPubMedCentral

21.

Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A: PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13: 2129-2141. 10.1101/gr.772403.CrossRefPubMedPubMedCentral

22.

Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP, Wasserman WW: oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 2005, 33: 3154-3164. 10.1093/nar/gki624.CrossRefPubMedPubMedCentral

23.

Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al: TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003, 31: 374-378. 10.1093/nar/gkg108.CrossRefPubMedPubMedCentral

24.

Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, et al: Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 2009, 10: 135-10.1186/1471-2164-10-135.CrossRefPubMedPubMedCentral

25.

Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001, 61: 4660-4665.PubMed

26.

Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, et al: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009, 41: 991-995. 10.1038/ng.421.CrossRefPubMedPubMedCentral

27.

Rosebeck S, Leaman DW: Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis. 2008, 13: 562-572. 10.1007/s10495-008-0190-0.CrossRefPubMed

28.

Santodonato L, Ferrantini M, Palombo F, Aurisicchio L, Delmastro P, La Monica N, Di Marco S, Ciliberto G, Du MX, Taylor MW, Belardelli F: Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Ther. 2001, 8: 63-72. 10.1038/sj.cgt.7700274.CrossRefPubMed

29.

Claudinon J, Monier MN, Lamaze C: Interfering with interferon receptor sorting and trafficking: impact on signaling. Biochimie. 2007, 89: 735-743. 10.1016/j.biochi.2007.03.014.CrossRefPubMed

30.

Kimberley FC, Sivasankar B, Paul Morgan B: Alternative roles for CD59. Mol Immunol. 2007, 44: 73-81. 10.1016/j.molimm.2006.06.019.CrossRefPubMed

31.

Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M: Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000, 60: 5522-5528.PubMed

32.

Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H: Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006, 119: 2428-2434. 10.1002/ijc.22097.CrossRefPubMed

33.

Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A: Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007, 67: 1121-1131. 10.1002/pros.20608.CrossRefPubMed

34.

Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W: Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med. 2007, 9: 715-726. 10.1002/jgm.1067.CrossRefPubMed

35.

Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM: Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008, 68: 861-869. 10.1158/0008-5472.CAN-07-0445.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/129/prepub

Title: Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways
Authors: Emanuele Marra
Paolo Uva
Valentina Viti
Valeria Simonelli
Eugenia Dogliotti
Emanuele De Rinaldis
Armin Lahm
Nicola La Monica
Alfredo Nicosia
Gennaro Ciliberto
Fabio Palombo
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-129

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial

Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells

E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell - endothelial cell interaction

Keynote webinar | Spotlight on antibody–drug conjugates in cancer